Pharmaceutical Technology

JANUARY 4, 2024

U-01 is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for Refractory Acute Myeloid Leukemia.… …

Medicine 100

Medicine Clinical Development Development 100

Pharma Mirror

FEBRUARY 25, 2022

This joint service offering, DRIVE™-Biologics, will leverage Abzena’s strength in design and developability, and cell line development through to commercial manufacturing.

Clinical Development 130

Clinical Development Development Manufacturing Medicine 130

Pharmaceutical Technology

NOVEMBER 18, 2023

Amphotericin B is under clinical development by Cystetic Medicines and currently in Phase I for Cystic Fibrosis.

Medicine 100

Medicine Clinical Development Development 100

Pharmaceutical Technology

APRIL 3, 2023

Ablaze Pharmaceuticals is set to develop a new GPC3-targeted peptide drug candidate for the treatment of liver cancer in China. The agreement allows Ablaze to clinically develop and commercialise the drug in Greater China. The company is licensing the first-in-class drug candidate under an existing deal with RayzeBio.

Development 246

Development Drugs Clinical Development Licensing 246

BioSpace

SEPTEMBER 15, 2020

Clinical-stage biopharmaceutical firm ESCAPE Bio has snagged a $73 million crossover financing deal, led by Wellington Management Company, which will help advance the company’s two clinical development programs of precision neurology medicines for patients with genetic neurodegeneration.

Clinical Development 96

Clinical Development Development Genetics Medicine 96

Pharmaceutical Technology

APRIL 12, 2023

Cognizant and Boehringer Ingelheim are collaborating on an integrated cloud platform to enhance the speed and quality of medicinal therapy development. Cognizant will leverage the Veeva Development Cloud platform to help Boehringer Ingelheim to merge medicinal development processes and data into a connected technology ecosystem.

Medicine 130

Medicine Life Science Development Branding 130

Pharmaceutical Technology

MAY 12, 2023

The Technical University of Denmark (DTU) has announced that an international scientific team has developed a CRISPR-based drug candidate that targets E coli directly and leaves the microbiome intact. The division of infectious diseases at Weill Cornell Medicine carried out the work in collaboration with JAFRAL and JMI Laboratories.

Development 246

Development Bacteria Research Gene Editing 246

Pharmaceutical Technology

OCTOBER 28, 2022

Drug discovery and development is an incredibly expensive and time-consuming process, taking between 12 and 18 years, and costing on average between $2 billion and $3 billion. Robots can improve drug discovery and development. Lab-specific industrial co-bots can carry out both complex and repetitive tasks such as liquid handling.

Development 311

Development Drugs Pharma Companies Life Science 311

Pharmaceutical Technology

NOVEMBER 21, 2022

RVAC Medicines has signed a master research partnership agreement with the Agency for Science, Technology and Research (A*STAR) for analysing and developing solutions to build messenger ribonucleic acid (mRNA) manufacturing and analytics expertise in Singapore. Topic sponsors are not involved in the creation of editorial content.

Manufacturing 130

Manufacturing Medicine Vaccination Vaccine 130

Pharmaceutical Technology

MAY 24, 2023

Forge Biologics has joined the public-private collaboration, the Bespoke Gene Therapy Consortium (BGTC), to expedite the development and manufacture of new AAV [adeno-associated virus] gene therapies to treat patients with rare diseases. Shilling was appointed to represent the company on the steering committee of the BGTC.

Gene Therapy 242

Gene Therapy Gene Development Manufacturing 242

Pharmaceutical Technology

AUGUST 11, 2022

Gemini Therapeutics has signed a definitive agreement to merge with Disc Medicine in an all-stock deal to create a clinical-stage biopharmaceutical company. The merged company is expected to be named Disc Medicine, which will have corporate headquarters in Watertown, Massachusetts, US.

Medicine 147

Medicine Clinical Trials Clinical Trials Licensing 147

Pharmaceutical Technology

OCTOBER 25, 2022

BioMed X has entered a research partnership with Sanofi to leverage artificial intelligence (AI) for drug development. The partnership intends to address a 90% failure rate of new therapy candidates in clinical development, which is a key bottleneck of the pharmaceutical industry.

Development 246

Development Drugs In-Vivo Engineer 246

Outsourcing Pharma

MAY 14, 2024

Today (May 14) Everest Medicines, a biopharmaceutical company focused on progressive medicines and vaccines, announced the successful launch of small molecule Nefecon, a delayed-release capsule, in China, with the first prescription issued.

Medicine 75

Medicine Vaccination Vaccine Clinical Development 75

Pharmaceutical Technology

JULY 7, 2022

But scientists have struggled to find effective treatments for many of these diseases since the dawn of modern medicine. Although a high number of cell and gene therapies are in early-stage development, a new wave of approvals could be on its way. Securing the supply chain. The industry is moving at an unprecedented speed.

Gene Therapy 245

Gene Therapy Gene Medicine Genetics 245

Pharmaceutical Technology

JUNE 5, 2023

Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Prostate Cancer. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Buy the report here.

Medicine 100

Medicine Hormones Production Clinical Trials 100

Pharmaceutical Technology

MAY 11, 2023

Bayer has entered a strategic collaboration agreement with biotechnology company Bicycle Therapeutics to discover, develop, manufacture and commercialise Bicycle’s radioconjugates for a number of oncology targets. Bicycle will receive an upfront payment of $45m and up to $1.7bn as potential development and commercially based milestone fees.

Development 162

Development Manufacturing Protein Clinical Development 162

Pharmaceutical Technology

MAY 26, 2023

HanAll Biopharma and Daewoong Pharmaceutical have entered into a co-development deal with NurrOn Pharmaceuticals to develop therapy for Parkinson’s disease (PD) and other neurodegenerative disorders. Nurr1 is a class of proteins important for the development and maintenance of dopamine in the brain.

Development 130

Development Clinical Trials Clinical Trials Protein 130

Pharmaceutical Technology

JUNE 5, 2023

Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Liver Failure (Hepatic Insufficiency). GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Medicine 100

Medicine Hormones Production Clinical Trials 100

BioPharma Reporter

MARCH 3, 2021

The number of advanced therapy medicinal product (ATMP) clinical trials in the UK continues to increase year on year with 154 ongoing trials observed in 2020, demonstrating the appeal of that market for the clinical development of ATMPs, shows a new report.

Clinical Development 52

Clinical Development Development Clinical Trials Clinical Trials 52

The Pharma Data

MAY 8, 2021

Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study, shortly 1. Aflibercept is a key treatment in ophthalmology.

Clinical Development 52

Clinical Development Medicine Development Containment 52

Outsourcing Pharma

MARCH 11, 2024

On March 7, Celadon Pharmaceuticals plc, a leading UK-based pharmaceutical company specializing in cannabis-based medicines, unveiled promising findings from an early economic analysis of its chronic pain clinical trial, dubbed CANPAIN.

Medicine 123

Medicine Clinical Trials Clinical Trials Trials 123

Drug Discovery World

DECEMBER 22, 2023

The trial met all pharmacokinetic objectives, so the company plans to progress the candidate into further clinical development and will meet with the US Food and Drug Administration (FDA) at a Pre-IND meeting in the first half of 2024. We now look forward to the next stage of clinical development.”

Medicine 52

Medicine Bioavailability Clinical Development Trials 52

Pharmaceutical Technology

MARCH 30, 2023

In the US, African American women are more likely to develop lupus than white or Caucasian women. In a 29 March press release, the FDA stated that Lupus ABC will bring voices together in a centralised forum to define challenges in drug development and analyse potential approaches to help advance therapies.

Development 162

Development Drugs FDA Approval Clinical Development 162

BioTech 365

DECEMBER 10, 2020

STALICLA Translates its Novel Precision Medicine Approach for Autism Spectrum Disorder into Clinical Development with First Patient in Phase 1b Trial of STP1 STALICLA Translates its Novel Precision Medicine Approach for Autism Spectrum Disorder into Clinical Development with First Patient … Continue reading →

Clinical Development 52

Clinical Development Medicine Development Trials 52

Pharmaceutical Technology

AUGUST 24, 2022

Lacerta Therapeutics has entered a new licensing and research partnership agreement with Eli Lilly and Company subsidiary, Prevail Therapeutics, to discover and develop adeno-associated virus (AAV) capsids for treating central nervous system (CNS) diseases. . Topic sponsors are not involved in the creation of editorial content.

Development 130

Development Gene Therapy Genetics Gene 130

Worldwide Clinical Trials

DECEMBER 7, 2023

These survey results also highlight the importance of evaluating a variety of potential CRO partners of different sizes to choose the best match for your clinical development goals and corporate culture. At Worldwide, we understand that every program is different, which means every drug development path forward will be unique.

Clinical Development 340

Clinical Development Clinical Trials Clinical Trials Trials 340

Outsourcing Pharma

SEPTEMBER 14, 2023

Insilico Medicine is due to receive $80 million upfront plus potential milestone payments as Exelixis gains global rights to develop and commercialize the Hong Kong firmâs small molecule cancer treatment.

Medicine 88

Medicine Licensing Licensing Drugs 88

Pharmaceutical Technology

OCTOBER 3, 2022

Indonesia has granted Emergency Use Authorization (EUA) for the patent-free Covid-19 vaccine, IndoVac, developed by the Texas Children’s Hospital Center for Vaccine Development (CVD) and Baylor College of Medicine, US. PT Bio Farma will manufacture 20 million doses of the vaccine this year.

Vaccination 130

Vaccination Vaccine Development Production 130

The Pharma Data

MARCH 23, 2022

Baynes, head of Global Clinical Development (GCD) and Chief Medical Officer, Merck Research Laboratories (MRL), will be retiring from Merck in July. Under his leadership, Merck has become a leading oncology company and achieved more than 140 medicine and vaccine approvals globally across numerous therapeutic areas.

Clinical Development 52

Clinical Development Development Vaccination Vaccine 52

Drug Discovery World

JANUARY 11, 2024

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. The post New podcast: Revolutionary technology for drug discovery and development appeared first on Drug Discovery World (DDW).

Development 59

Development Drugs Genome Genomics 59

Pharmaceutical Technology

AUGUST 30, 2022

Zerion Pharma has entered a partnership with Insud Pharma for the development and marketing of drug products using Zerion Pharma's solubility-boosting Dispersome technology. . Under the deal, Zerion will handle the development of Dispersome formulations of marketed drugs.

Development 130

Development Drugs Bioavailability Production 130

Pharmaceutical Technology

NOVEMBER 18, 2022

Regeneron Pharmaceuticals has entered a collaboration and licensing agreement with CytomX Therapeutics for developing conditionally-activated bispecific cancer therapies. This collaboration will use Regeneron’s Veloci-Bi bispecific antibody development platform and CytomX's Probody therapeutic platform.

Development 130

Development Antibody Licensing Licensing 130

Pharmaceutical Technology

FEBRUARY 13, 2023

SOPHiA GENETICS is expanding its collaboration with AstraZeneca to include multimodal approaches for developing cancer drugs. The post SOPHiA GENETICS and AstraZeneca partner for oncology drugs development appeared first on Pharmaceutical Technology.

Genetics 130

Genetics Development Drugs Genome 130

Pharmaceutical Technology

AUGUST 4, 2022

Poseida Therapeutics and Roche have signed a strategic partnership and licence agreement to develop allogeneic CAR-T cell therapies for hematologic malignancies. Roche and Poseida will also partner in a research programme for creating and developing next-generation features and enhancements for allogeneic CAR-T therapies.

Development 147

Development Clinical Trials Clinical Trials Gene Therapy 147

Pharmaceutical Technology

DECEMBER 7, 2022

Pfizer has entered a research partnership and exclusive licence agreement with Clear Creek Bio to progress new SARS-CoV-2 papain-like protease (PLpro) inhibitors’ discovery and development for the oral treatment of Covid-19. On entering the clinic, Pfizer will solely handle the development and marketing works of the candidate.

Development 130

Development Clinical Trials Clinical Trials Sales 130

Scienmag

OCTOBER 20, 2021

Marseille, France, October 20, 2021 – ImCheck Therapeutics announced today the publication of the preclinical to clinical development of its lead immuno-oncology program, ICT01.

Medicine 75

Medicine Development Clinical Development 75

The Pharma Data

MAY 2, 2021

With eight marketed biosimilar medicines globally and 15+ molecules in pipeline, Sandoz is investing in future of biosimilars for patients and healthcare systems. Holzkirchen, May 3, 2021 – Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept.

Clinical Development 40

Clinical Development Medicine Development Production 40